1-(3-chlorophenyl)piperazine has been researched along with Depressive Disorder in 21 studies
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure
1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol at 4 mg/day was coadministered for 1 week, and blood samplings were taken before and after the coadministration." | 2.68 | Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. ( Ishida, M; Kaneko, S; Mihara, K; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K; Suzuki, A; Yasui, N, 1997) |
| " For both trazodone and mCPP, significant linear relationships were found between plasma concentration after initial dosing and the average of 3 weeks' plasma concentrations." | 1.30 | Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone. ( Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K; Tokinaga, N; Yasui, N, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 16 (76.19) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mihara, K | 4 |
| Yasui-Furukori, N | 1 |
| Kondo, T | 2 |
| Ishida, M | 4 |
| Ono, S | 1 |
| Ohkubo, T | 5 |
| Osanai, T | 4 |
| Sugawara, K | 5 |
| Otani, K | 5 |
| Kaneko, S | 5 |
| Kubera, M | 1 |
| Maes, M | 1 |
| Kenis, G | 1 |
| Kim, YK | 1 |
| Lasoń, W | 1 |
| Yasui, N | 4 |
| Fukushima, Y | 1 |
| Anand, A | 1 |
| Charney, DS | 1 |
| Delgado, PL | 1 |
| McDougle, CJ | 2 |
| Heninger, GR | 2 |
| Price, LH | 2 |
| Thakore, JH | 1 |
| Pitchot, W | 1 |
| Ansseau, M | 1 |
| Gonzalez Moreno, A | 1 |
| Hansenne, M | 1 |
| Suzuki, A | 2 |
| Tokinaga, N | 1 |
| Nakano, H | 1 |
| Meng, X | 1 |
| Nagasaki, T | 1 |
| Tsuchida, S | 1 |
| Gonzalez, FJ | 1 |
| Malison, RT | 1 |
| McCance-Katz, EF | 1 |
| Owen, KR | 1 |
| Steiger, H | 1 |
| Gauvin, L | 1 |
| Israël, M | 1 |
| Koerner, N | 1 |
| Ng Ying Kin, NM | 1 |
| Paris, J | 1 |
| Young, SN | 1 |
| Overstreet, DH | 1 |
| Rezvani, AH | 1 |
| Janowsky, DS | 1 |
| Asnis, GM | 4 |
| Wetzler, S | 4 |
| Sanderson, WC | 1 |
| Kahn, RS | 4 |
| van Praag, HM | 4 |
| Brewerton, TD | 1 |
| Mueller, EA | 2 |
| Lesem, MD | 1 |
| Brandt, HA | 1 |
| Quearry, B | 1 |
| George, DT | 1 |
| Murphy, DL | 3 |
| Jimerson, DC | 1 |
| Workman, EA | 1 |
| Tellian, F | 1 |
| Short, D | 1 |
| Korn, M | 1 |
| Bihari, K | 1 |
| Pato, MT | 1 |
| Hill, JL | 1 |
| Papolos, D | 1 |
| Mellow, AM | 1 |
| Lawlor, BA | 1 |
| Sunderland, T | 1 |
| Molchan, SE | 1 |
| Zohar, J | 1 |
| Insel, TR | 1 |
| Strauman, T | 1 |
10 trials available for 1-(3-chlorophenyl)piperazine and Depressive Disorder
| Article | Year |
|---|---|
Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depressive Di | 2002 |
Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
Topics: Adult; Affect; Biomarkers; Depressive Disorder; Double-Blind Method; Female; Growth Hormone; Humans; | 1994 |
Responses to mCPP stimulation in depressed patients.
Topics: Depressive Disorder; Double-Blind Method; Growth Hormone; Humans; Hydrocortisone; Male; Piperazines; | 1995 |
Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cytochrome P-450 CYP2D6 Inhib | 1997 |
Neurobiology of tryptophan depletion in depression: effects of m-chlorophenylpiperazine (mCPP).
Topics: Adult; Affect; Aged; Amino Acids; Depressive Disorder; Double-Blind Method; Female; Human Growth Hor | 1997 |
Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects.
Topics: Adult; Depressive Disorder; Desipramine; Female; Humans; Hydrocortisone; Male; Middle Aged; Norepine | 1992 |
Serotonin receptor sensitivity and aggression.
Topics: Adult; Aggression; Anger; Anxiety Disorders; Depressive Disorder; Double-Blind Method; Female; Human | 1991 |
Serotonin receptor sensitivity in major depression.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Humans; Hydrocortisone; M | 1990 |
Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients. Initial experience with a serotonin agonist.
Topics: Aged; Antidepressive Agents; Brain; Depressive Disorder; Double-Blind Method; Female; Humans; Male; | 1990 |
Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Topics: Adult; Brain; Clomipramine; Depressive Disorder; Desipramine; Diagnosis, Differential; Female; Human | 1987 |
11 other studies available for 1-(3-chlorophenyl)piperazine and Depressive Disorder
| Article | Year |
|---|---|
Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fenclonine; Humans; Immunocomp | 2005 |
Trazodone treatment increases plasma prolactin concentrations in depressed patients.
Topics: Adult; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Prola | 1995 |
Responses to mCPP stimulation in depressed patients.
Topics: Depressive Disorder; Female; Growth Hormone; Humans; Hydrocortisone; Male; Menstrual Cycle; Piperazi | 1995 |
Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone.
Topics: Adult; Aged; Depressive Disorder; Female; Humans; Male; Middle Aged; Piperazines; Trazodone | 1997 |
Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Depressive Disorder; Femal | 1997 |
Association of serotonin and cortisol indices with childhood abuse in bulimia nervosa.
Topics: Adolescent; Adult; Blood Platelets; Bulimia; Carrier Proteins; Child; Child Abuse; Child Abuse, Sexu | 2001 |
Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcohol Drinking; Alcoholism; Animals; Arousal; Avoidance Le | 1992 |
Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia.
Topics: Adult; Age Factors; Body Weight; Bulimia; Circadian Rhythm; Depressive Disorder; Diagnosis, Differen | 1992 |
Trazodone induction of migraine headache through mCPP.
Topics: Adult; Depressive Disorder; Humans; Male; Migraine Disorders; Piperazines; Trazodone | 1992 |
Neurologic soft signs in obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Central Nervous System Diseases; Clomipramine; Clonidine; Depressive Disor | 1991 |
Behavioral indications for serotonin receptor hypersensitivity in panic disorder.
Topics: Adult; Brain; Depressive Disorder; Fear; Female; Humans; Infusions, Intravenous; Male; Panic; Pipera | 1988 |